Detalhe da pesquisa
1.
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 27(12): 1041-1047, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979929
2.
CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
Cancer Invest
; 40(10): 923-937, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36102932
3.
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
BMC Cancer
; 21(1): 1292, 2021 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34856936
4.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol
; 20(4): 581-590, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827746
5.
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Curr Treat Options Oncol
; 20(5): 44, 2019 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31054006
6.
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Clin Nucl Med
; 48(9): 775-780, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385221
7.
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Cancers (Basel)
; 15(4)2023 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831409
8.
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study.
EClinicalMedicine
; 60: 102018, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37304495
9.
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Prostate Cancer Prostatic Dis
; 25(2): 199-207, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108647
10.
Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
Clin Genitourin Cancer
; 20(6): 568-574, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36127252
11.
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Cancer Treat Rev
; 99: 102239, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157582
12.
Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
Cancers (Basel)
; 13(17)2021 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34503152
13.
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Front Oncol
; 11: 671969, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34094973
14.
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Minerva Urol Nephrol
; 73(3): 292-298, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33781027
15.
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
JAMA Oncol
; 7(12): 1815-1823, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34673916
16.
Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?
Minerva Urol Nefrol
; 72(6): 663-672, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32993274
17.
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Cancers (Basel)
; 12(7)2020 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32709062
18.
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
J Immunother Cancer
; 8(2)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33177176
19.
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32217762
20.
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
J Immunother Cancer
; 8(1)2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32066646